Impfungen bei rheumatischen Erkrankungen

Zusammenfassung

Rheumatische Erkrankungen und insbesondere deren immunsuppressive Therapie sind mit einem erhöhten Infektionsrisiko und entsprechend erhöhter Morbidität und Mortalität verbunden. Vielen dieser Infektionen kann durch Impfung vorgebeugt werden. Aktuelle Daten der Versorgungsforschung zeigen, dass dennoch Impfungen bei Patienten mit entzündlich rheumatischen Erkrankungen aufgrund von Unsicherheiten bezüglich Impferfolg und Nebenwirkungen sowie organisatorischen Schwierigkeiten nur unzureichend umgesetzt werden. Dieser Beitrag gibt einen Überblick über die aktuellen Impfempfehlungen der STI-KO sowie der Fachgesellschaften EULAR und DGRh bei erwachsenen Patienten mit entzündlich rheumatischen Erkrankungen.

Summary

Patients suffering from rheumatic diseases are known to have an increased risk of infectious morbidity and mortality due to both the underlying disease itself and the immunosuppressive therapy. Many of these infections are preventable by vaccination. Yet data from health services research show insufficient vaccination status in these patients because of concerns in regard to vaccination response, side effects and because of organisational difficulties. This article reviews the current national and European recommendations for vaccination of adult patients with rheumatic disease.

Schlüsselwörter

Impfung - rheumatische Erkrankung - Immunsuppression

Keywords

Vaccination - rheumatic disease - immunosuppression

• Literatur

• 1 Widdifield J, Bernatsky S, Paterson JM. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis care & research 2013; 65: 353-361.
• 2 Zink A, Manger B, Kaufmann J. et al. Evaluation of the RABBIT Risk Score for serious infections. Annals of the rheumatic diseases. 2013 June 5, online first
• 3 Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am 2009; 35 (01) 75-93.
• 4 Atzeni F, Bendtzen K, Bobbio-Pallavicini F. et al. Infections and treatment of patients with rheumatic diseases. Clinical & Experimental Rheumatology 2008; 26 (01) (Suppl. 48) S67-S73.
• 5 Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15: 335-361 vii
• 6 Feuchtenberger M, Kleinert S, Schwab S. et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 2012; 32: 1533-1539.
• 7 Fahy WA, Farnworth E, Yeldrem KP. et al. Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy. Rheumatology (Oxford) 2006; 45 (07) 912-913.
• 8 Goldacker S, Gause AM, Warnatz K. [Vaccination in adult patients with chronic inflammatory rheumatic diseases]. Zeitschrift fur Rheumatologie 2013; 72: 690-704.
• 9 van Assen S, Agmon-Levin N, Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-422.
• 10 Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 2005; 46: 997-1011.
• 11 Louie JS, Nies KM, Shoji KT. et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88 (06) 790-792.
• 12 Ristow SC, Douglas Jr. RG, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978; 88 (06) 786-789.
• 13 van Assen S, Holvast A, Benne CA. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis & Rheumatism 2010; 62 (01) 75-81.
• 14 Edwards JC, Szczepanski L, Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350 (25) 2572-2581.
• 15 Cambridge G, Leandro MJ, Teodorescu M. et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis & Rheumatism 2006; 54 (11) 3612-3622.
• 16 Venhoff N, Effelsberg NM, Salzer U. et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PloS one 2012; 7: e37626.
• 17 Dias AM, do Couto MC, Duarte CC. et al. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Ann N Y Acad Sci 2009; 1173: 103-107.
• 18 Jeong SJ, Choi H, Lee HS. et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 2009; 41: 268-274.
• 19 Nath R, Mant C, Luxton J. et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis & Rheumatism 2007; 57 (04) 619-625.
• 20 Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Annals of the rheumatic diseases 2013; 72: 659-664.